Modulation of dopamine D <sub>1</sub> receptors via histamine H <sub>3</sub> receptors is a novel therapeutic target for Huntington’s disease
David Moreno‐Delgado(Galapagos (Belgium)), Peter J. McCormick(Queen Mary University of London), Anna Chiarlone(Universidad Complutense de Madrid), Carme Lluı́s(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Vicent Casadó(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marco Scarselli(University of Pisa), Jordi Alberch(Centro de Investigación Biomédica en Red), Enric I. Canela(Biomedical Research Networking Center on Neurodegenerative Diseases), Paola Gasperini(University of Trento), Sílvia Ginés(Instituto de Salud Carlos III), Mar Rodríguez-Ruiz(Biomedical Research Networking Center on Neurodegenerative Diseases), Antoni Cortés(Biomedical Research Networking Center on Neurodegenerative Diseases), Estefanía Moreno(Institute for Research in Biomedicine), Manuel Guzmán(Universidad Complutense de Madrid), Mar Puigdellívol(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sergi Ferré(National Institute on Drug Abuse), Lesley A. Howell(Queen Mary University of London), Joaquín Botta
Cited by 0
Related Papers
Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids
|Neuropsychopharmacology|2007|249
Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice
|Nature Neuroscience|2017|235
Identification of Dopamine D1–D3 Receptor Heteromers
|Journal of Biological Chemistry|2008|230